Accéder au contenu
Merck

Cytotoxicity of anticancer candidate salinomycin and identification of its metabolites in rat cell cultures.

Toxicology in vitro : an international journal published in association with BIBRA (2018-07-18)
Lidia Radko, Małgorzata Olejnik
RÉSUMÉ

Salinomycin (SAL) is a polyether antibiotic, which is commonly used as a coccidiostat and has recently shown to exhibit anticancer activity. The toxic action of the drug may be connected with the extent and routes of its biotransformation. The cytotoxic potential of SAL and its combination with tiamulin and prednisolone was investigated using three cell models from rat: primary hepatocytes, hepatoma cells (FaO) and myoblasts (L6). The four biochemical endpoints were assessed: mitochondrial and lysosomal activity, total cell protein content and membrane integrity. The metabolites of SAL in the medium from cell cultures were determined using LC-MS/MS. The cytotoxicity of SAL was time-, concentration- and cells dependent. The most sensitive endpoint was the inhibition of lysosomal activity. Tiamulin increased SAL cytotoxicity, whereas the opposite results were observed for prednisolone. Primary hepatocytes were the most efficient in SAL biotransformation both in terms of its intensity and number of produced metabolites. The range of the cytotoxicity and mode of salinomycin interaction with tiamulin and prednisolone cannot be explained by the biotransformation alone.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Salinomycin SV Sodium salt Penta hemihydrate, VETRANAL®, analytical standard